1,2,3,4-四氢异喹啉-2-胺 | 4836-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,2,3,4-四氢异喹啉-2-胺
• 英文名称: 3,4-dihydroisoquinolin-2(1H)-amine
• 英文别名: N-amino-1,2,3,4-tetrahydroisoquinoline；N-Amino-1,2,3,4-tetrahydro-isochinolin；1,2,3,4-tetrahydro-2-amino-isoquinoline；Isoquinoline, 1,2,3,4-tetrahydro-2-amino-；3,4-dihydro-1H-isoquinolin-2-amine
• CAS: 4836-98-0
• 化学式: C₉H₁₂N₂
• mdl: MFCD00156260
• 分子量: 148.208
• InChiKey: IYANYSZUKHQLKL-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 0.5 Torr)
• 密度：
  1.098±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢异喹啉-2-胺 在 lithium aluminium tetrahydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 0.84h， 生成 N-methyl-3,4-dihydroisoquinolin-2(1H)-amine
  参考文献：
  名称：

  Discovery and structural analyses of S-adenosyl-l-homocysteine hydrolase inhibitors based on non-adenosine analogs

  摘要：

  Optimization of a new series of S-adenosyl-L-homocysteine hydrolase (AdoHcyase) inhibitors based on non-adenosine analogs led to very potent compounds 14n, 18a, and 18b with IC50 values of 13 +/- 3, 5.0 +/- 2.0, and 8.5 +/- 3.1 nM, respectively. An X-ray crystal structure of AdoHcyase with NAD(+) and 18a showed a novel open form co-crystal structure. 18a in the co-crystals formed intramolecular eight membered ring hydrogen bond formations. A single crystal X-ray structure of 14n also showed an intramolecular eight-membered ring hydrogen bond interaction. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.018
• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉 盐酸盐 在 sodium nitrate 、 四氯化钛 、 magnesium 作用下， 以 乙醚 、 水 、 溶剂黄146 、 1,2-二氯乙烷 为溶剂， 反应 2.5h， 生成 1,2,3,4-四氢异喹啉-2-胺
  参考文献：
  名称：

  Landriani; Barlocco; Pinna, Il Farmaco, 1989, vol. 44, # 11, p. 1059 - 1068

  摘要：

  DOI：

文献信息

• Relay Visible-Light Photoredox Catalysis: Synthesis of Pyrazole Derivatives via Formal [4 + 1] Annulation and Aromatization
  作者：Jian Cheng、Weipeng Li、Yingqian Duan、Yixiang Cheng、Shouyun Yu、Chengjian Zhu

  DOI：10.1021/acs.orglett.6b03497

  日期：2017.1.6

  A relay visible-light photoredox catalysis strategy has been accomplished. Three successive photoredox cycles (one oxidative quenching cycle and two reductive quenching cycles) are engaged in a single reaction with one photocatalyst. This strategy enables formal [4 + 1] annulation of hydrazones with 2-bromo-1,3-dicarbonyl compounds, which functionalizes three C–H bonds of hydrazones. This method affords

  继电器可见光光氧化还原催化策略已完成。三个连续的光氧化还原循环（一个氧化性淬灭循环和两个还原性淬灭循环）与一种光催化剂进行单个反应。这种策略可以使与2-溴-1,3-二羰基化合物进行正式的[4 +1]环化反应，从而使的三个C–H键官能化。该方法可在温和条件下以分步经济的方式快速高效地获得复杂且对生物学重要的吡唑支架。
• [EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009020990A1

  公开（公告）日：2009-02-12

  Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  新型吡咯吡嘧啶如公式(I)所示，及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Copper(II)-catalyzed-α-C(sp3)-H activation of cyclic amines: A simple and efficient strategy for the synthesis of fused pyrazole derivatives
  作者：Venkata Reddy Regalla、RamaKrishnam Raju Addada、Anindita Chatterjee

  DOI：10.1016/j.tetlet.2018.10.017

  日期：2018.11

  and efficient strategy for the synthesis of fused pyrazole derivatives. The key steps of our strategy involves hydroamination, copper-catalyzed cross dehydrogenative coupling (CDC) followed by aromatization (aerial oxidation) in one-pot. Our strategy offers a valuable alternative to known methods for synthesis of fused pyrazole derivatives. Overall, we have synthesized 13 diverse fused pyrazole derivatives

  在本文中，我们描述了一种简单而有效的策略，用于合成稠合的吡唑衍生物。我们策略的关键步骤包括加氢胺化，铜催化的交叉脱氢偶联（CDC），然后在一个锅中进行芳构化（航空氧化）。我们的策略为合成稠合吡唑衍生物的已知方法提供了有价值的替代方法。总体而言，我们以中等至出色的产率合成了13种不同的稠合吡唑衍生物。